Hiroya Tamai, EULAR 2022: MIRACLE Study of Adalimumab with Low and High Dose-methotrexate in RA
The MIRACLE study investigated the optimal dose of methotrexate when used in combination with adalimumab for rheumatoid arthritis. touchIMMUNOLOGY caught up with Dr. Hiroya Tamai (Keio University School of Medicine, Tokyo, Japan) to discuss the findings from this study and the conclusions of the investigators.
The abstract ‘Efficacy and safety of adalimumab with low and high dose-methotrexate in patients with rheumatoid arthritis with inadequate response to methotrexate: the randomised controlled MIRACLE study.’ (Abstract number: OP0062) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What was the rationale for your study investigating the optimal dose of methotrexate when used in combination with adalimumab for rheumatoid arthritis (RA)? (0:11)
- What were the aims, design and eligibility criteria of the MIRACLE study? (1:51)
- What were the clinical endpoints of the MIRACLE study? (2:53)
- How well were these endpoints achieved? (3:23)
- What were the conclusions of the investigators in regards to using a reduced dose of concomitant methotrexate with adalimumab for RA? (4:23)
Disclosures: Hiroya Tamai discloses receiving grant/ research support from and speaker’s bureau participation for Eisai.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
